Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's ...
Find MoreThe US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...
Find MoreHen’s egg allergy is the second most common type of allergy after cow’s milk. In infants and young children, Egg poses as one of the most vital allergens degrading the quality of life. As per estimates, as many as 2 per cents of children are allergic to eggs. However, around 70% of these children are fortunate ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.